Amgen vs Johnson & Johnson at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | AMGN | JNJ |
|---|---|---|
| Market cap | $241.45B | $666.49B |
| Price | $442.24 | $273.14 |
| P/E ratio (TTM) | 22.89 | 18.74 |
| P/B ratio (MRQ) | 20.38 | 6.16 |
| P/S ratio (TTM) | 4.8 | 5.33 |
| Revenue growth (1Y) | 9.92% | 6.05% |
| Return on equity (TTM) | 89.06% | 32.87% |
| Return on invested capital (TTM) | 14.50% | 16.26% |
| Gross margin (TTM) | 72.65% | 75.17% |
| Net margin (TTM) | 22.93% | 21.48% |
| Dividend yield (TTM) | 2.27% | 1.96% |
How they differ
Johnson & Johnson is the larger company at $666.49B versus $241.45B — about 2.8x the size.
On trailing earnings, Johnson & Johnson is the cheaper of the two at 18.74 against 22.89 for Amgen.
On sales, Amgen is the cheaper of the two at 4.8 against 5.33 for Johnson & Johnson.
Amgen leads on revenue growth over the past year, 9.92% against 6.05%.
Johnson & Johnson leads on return on invested capital, 16.26% against 14.50%.
Johnson & Johnson leads on gross margin, 75.17% against 72.65%.
Amgen offers the higher yield at 2.27% against 1.96%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Amgen or Johnson & Johnson.